Paper Details

  1. Home
  2. Paper Details

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.

Author: , BabikerAbdel G, EmerySean, FätkenheuerGerd, GordinFred M, GrundBirgit, LundgrenJens D, NeatonJames D, PettSarah L, PhillipsAndrew, TouloumiGiota, VjechajMichael J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Untreated HIV infection causes a decrease in a type of immune cell (CD4 count), leading to infections and AIDS. Recent research suggests that HIV also increases the risk of other serious illnesses, including heart, kidney, and liver disease, and certain cancers. While combination antiretroviral therapy (ART) has significantly improved health outcomes, it does not eliminate the virus. The best time to start ART for people with HIV who are not experiencing symptoms is still debated and is a critical question in managing HIV infection.
Paper Details　
Original Abstract of the Article :
Untreated human immunodeficiency virus (HIV) infection is characterized by progressive depletion of CD4+ T lymphocyte (CD4) count leading to the development of opportunistic diseases (acquired immunodeficiency syndrome (AIDS)), and more recent data suggest that HIV is also associated with an increas...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/22547421

データ提供：米国国立医学図書館（NLM）

Navigating the START Study: When to Begin Antiretroviral Treatment for HIV

In the clinical management of HIV, we face a desert of uncertainty about when to start antiretroviral treatment. The START study, a beacon of research, explores this crucial question. Like a compass guiding us through this vast landscape, the START study seeks to determine the optimal time to begin treatment for individuals with asymptomatic HIV infection.

The study acknowledges the profound impact of untreated HIV infection. It's like a slow-burning fire, gradually depleting the immune system and leading to various health complications. While antiretroviral therapy, a potent weapon against HIV, can significantly mitigate the damage, it's crucial to determine the best time to unleash its power. The START study aims to provide valuable insights into this complex issue.

The START Study's Significance

The START study represents a pivotal step in understanding the optimal timing of antiretroviral therapy for HIV. By shedding light on the impact of treatment initiation on long-term health outcomes, the study will inform clinical practice and improve the care of individuals with HIV.

Health Benefits and Practical Applications

The findings of the START study have the potential to significantly influence the management of HIV infection. By providing evidence-based guidance on treatment initiation, the study can contribute to improved health outcomes for individuals living with HIV. It's like finding a new oasis in the desert, offering a path towards a healthier future.

Dr. Camel's Conclusion

The START study is a landmark research endeavor that will shape our understanding of HIV treatment. By illuminating the optimal time to begin antiretroviral therapy, the study promises to improve the lives of countless individuals living with HIV.

Date :
  1. Date Completed 2014-01-06
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

22547421

DOI: Digital Object Identifier

NIHMS374013

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.